Oric Pharmaceuticals, Inc. ORIC Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -42.6%+5.9pp | -41.3%+13.5pp | -39.7%+6.2pp | -43.8%-5.0pp | -48.5%-10.2pp | |
| Return on assets | -39.8%+5.0pp | -37.9%+10.7pp | -36.9%+4.7pp | -40.6%-4.9pp | -44.8%-9.5pp | |
| Return on invested capital | -55.9%+9.4pp | -53%+17.7pp | -49.9%+9.1pp | -59.1%+0.1pp | -65.4%-11.2pp | |
| Liquidity | ||||||
| Current ratio | 16.3×+4.3× | 14.1×+3.6× | 14.6×+1.5× | 16.1×+1.1× | 12×-9.3× | |
| Quick ratio | 16.3×+4.3× | 14.1×+3.6× | 14.6×+1.5× | 16.1×+1.1× | 12×-9.3× | |
| Cash ratio | 3.2×+0.4× | 2.2×-0.2× | 2.5×+0.4× | 4.2×+1.7× | 2.8×-0.9× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $3.94+27.4% | $4.38+25.6% | $4.11+5.9% | $4.15-3.5% | $3.09-36.6% | |
| Valuation | ||||||
| Market capitalization | $976.17M+23.4% | $796.64M+39.9% | $1.17B+61.6% | $893.94M+79.7% | $396.33M-57.2% | |
| Enterprise value | $923.07M+23.9% | $758.42M+46.0% | $1.12B+64.6% | $821.35M+82.4% | $350.21M-59.9% | |
| Price / book | 2.4×-1.3× | 2.1×-0.3× | 2.9×+0.2× | 2.8×+1.1× | 1.8×-1.0× | |
| Free cash flow yield | -11.4%+3.3pp | -14%+6.0pp | -10.1%+5.2pp | -13.6%+6.6pp | -29.4%-19.0pp | |
| Earnings yield | -13.8%+2.9pp | -16.3%+6.2pp | -11.6%+5.0pp | -15.4%+6.9pp | -33.5%-22.5pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Oric Pharmaceuticals, Inc.'s ratios come from?
- Every ratio is computed from Oric Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.